BILLERICA, Mass.–(BUSINESS WIRE)–March 16, 2022–
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its Board of Directors, effective April 1, 2022.
This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220316005639/en/
Dr. Philip Ma is CEO, President and Founder of PrognomiQ (Photo: Business Wire)
Dr. Ma is Chief Executive Officer, Founder, and Director of PrognomiQ, a private healthcare company that develops transformative next-generation multiomics products to enable early detection of cancer and selection and monitoring of cancer treatments. Prior to PrognomiQ, Dr. Ma was Chief Commercial Officer, President and Co-Founder of the proteomics company Seer. Previously, he was Vice President of Digital Health Technology and Data Science at Biogen. Prior to joining Biogen, Dr. Ma was a senior partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotechnology industries, leading the West Coast healthcare practice and the global personalized medicine practice. Dr. Ma was a macromolecular crystallographer at the Massachusetts Institute of Technology, where he earned his Ph.D. in biology. Philip also holds an AB degree in Biochemistry from Harvard University and an M.Phil in Economics from Oxford University, where he was a Rhodes Scholar.
“We are very pleased to welcome Philip to Bruker’s Board of Directors. Philip brings a wealth of experience in life sciences, multiomics technology, cancer biomarker diagnostics and the global biopharmaceutical industry, including his recent experience as a co-founder of two highly innovative companies Philip also has extensive knowledge of molecular biology, proteomics and the latest in big data software and artificial intelligence/deep learning applications “Said Frank H. Laukien, Chairman, President and CEO of Bruker. “The addition of Philip to our Board of Directors is timely as we continue to advance our Project Accelerate 2.0 multiomics life science initiatives and clinical research tools. Philip shares our entrepreneurial culture of “Innovation with Integrity” and our goals of serving life science and medical research customers with differentiated, high-value systems and solutions to enhance value for all Bruker stakeholders.
“I am delighted to join Bruker’s Board of Directors at this important time in the company’s development. The future of life science research increasingly focuses on further exploring the interaction of proteins, nucleic acids and metabolites from a systems biology view of key mechanisms, including that of disease. The research and diagnostic products that Bruker provides today, and develops, will greatly enable this vision of research and healthcare. I look forward to working with Frank and the Bruker team to plan and work towards this exciting future,” commented Dr. Ma.
About Bruker Corporation
Bruker enables scientists to make groundbreaking discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at the molecular, cellular and microscopic levels. Working closely with our customers, Bruker enables innovation, improved productivity and customer success in life science molecular and cellular biology research, applied and pharmaceutical applications, microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostic systems and solutions in the areas of preclinical imaging, clinical phenomics research, proteomics and multiomics, space biology and unicellular, structural functional biology and condensates, as well as clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
Forward-looking statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. , as amended. All forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to , the risk factors discussed from time to time in our filings. with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in greater detail in our filings with the SEC, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as as updated by our quarterly reports on Form 10-Q. We expressly disclaim any intention or obligation to update these forward-looking statements other than as required by law.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220316005639/en/
CONTACT: Justin Ward, Senior Director, Investor Relations and Corporate Development
Bruker Corporation
Phone. : +1 (978) 663–3660
E: Investor.Relations@bruker.com
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICALS BIOTECHNOLOGY
SOURCE: Bruker Corporation
Copyright BusinessWire 2022.
PUBLISHED: 03/16/2022 09:46 / DISK: 03/16/2022 09:46